• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:20:26 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTR alert in real time by email
    false 0000906709 0000906709 2025-05-08 2025-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 8, 2025

     

    NEKTAR THERAPEUTICS

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   0-24006   94-3134940
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    455 Mission Bay Boulevard South

    San Francisco, California 94158

    (Address of Principal Executive Offices and Zip Code)

     

    Registrant’s telephone number, including area code: (415) 482-5300

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   NKTR   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 8, 2025, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1.

     

    The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description 
    99.1   Press release titled “Nektar Therapeutics Reports First Quarter 2025 Financial Results.”
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NEKTAR THERAPEUTICS
         
    Date: May 8, 2025 By: /s/ Mark A. Wilson
        Mark A. Wilson
        Chief Legal Officer and Secretary

     

     

    2

     

     

    Get the next $NKTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKTR

    DatePrice TargetRatingAnalyst
    4/11/2025$2.00Hold → Buy
    Jefferies
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    1/8/2025$4.00Buy
    B. Riley Securities
    12/10/2024$6.50Buy
    H.C. Wainwright
    11/4/2024$7.00Overweight
    Piper Sandler
    9/30/2024$4.00Buy
    BTIG Research
    6/28/2024$2.00Buy
    Rodman & Renshaw
    11/20/2023Underweight
    JP Morgan
    More analyst ratings

    $NKTR
    SEC Filings

    See more
    • Nektar Therapeutics filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

      6/6/25 4:30:13 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics filed SEC Form 8-K: Other Events

      8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

      6/4/25 4:30:08 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

      5/8/25 4:20:26 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief R&D Officer Zalevsky Jonathan sold $7,177 worth of shares (10,712 units at $0.67), decreasing direct ownership by 3% to 305,892 units (SEC Form 4)

      4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

      5/21/25 8:08:34 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Wilson Mark Andrew sold $6,697 worth of shares (9,996 units at $0.67), decreasing direct ownership by 3% to 314,296 units (SEC Form 4)

      4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

      5/21/25 8:07:50 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Robin Howard W sold $15,549 worth of shares (23,208 units at $0.67), decreasing direct ownership by 2% to 1,063,693 units (SEC Form 4)

      4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

      5/21/25 8:07:02 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care